Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11825919 | 1.00 | TSHR (0.51) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL2841941 | 0.92 | TSHR (0.43) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| Acrylic Acid Ethyl Ester SCHEMBL7225855 | 0.89 | TSHR (0.61) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL8396140 | 0.86 | TSHR (0.45) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL25275191 | 0.85 | TSHR (0.70) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL25228041 | 0.85 | TSHR (0.70) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL7111058 | 0.85 | TSHR (0.70) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL25281286 | 0.85 | TSHR (0.70) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL20503422 | 0.85 | TSHR (0.70) | TSHRALDH1A1CYP3A4HPGDHCAR2 | |
| SCHEMBL673261 | 0.85 | TSHR (0.70) | TSHRALDH1A1CYP3A4HPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641441-B1 | TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER | PURDUE PHARMA LP (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2319505-A1 | TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT IN A RATIO FROM 1:10 UP TO 10:1 | Purdue Pharma L.P. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2316440-A1 | Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent | Purdue Pharma L.P. (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-1641441-A2 | TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER | Purdue Pharma Ltd. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004098567-A2 | TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER | PURDUE PHARMA L.P. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1322299-A2 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL | 3M Innovative Properties Company (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026217-A2 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |